{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:35:06Z","timestamp":1790274906982,"version":"4.1.0"},"reference-count":177,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Silesia in Katowice, Poland","award":["BNW-1-012\/K\/3\/F"],"award-info":[{"award-number":["BNW-1-012\/K\/3\/F"]}]},{"name":"Medical University of Silesia in Katowice, Poland","award":["BNW-2-012\/K\/3\/F"],"award-info":[{"award-number":["BNW-2-012\/K\/3\/F"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Type 2 diabetes (T2DM) is a chronic metabolic disease with a steadily increasing prevalence worldwide. Diabetes affects the function of many organs, including the skin. Pharmacotherapy for T2DM is mainly based on oral hypoglycemic drugs. The therapeutic strategy is chosen taking into account the individual patient\u2019s characteristics, among other comorbidities. Antidiabetic drugs can induce cutaneous adverse reactions (CADRs) ranging in severity from mild erythema to serious disorders such as DRESS or Stevens\u2013Johnson syndrome. CADRs can result from hypersensitivity to the drug but can also be related to the mechanism of action of the drug or cross-reactivity with drugs of similar structure. This paper reviews CADRs induced by oral antidiabetic drugs, considering their dermatological manifestations and possible pathomechanisms. Particular attention was paid to specific dermatological conditions such as dipeptidylpeptidase 4 inhibitor-associated bullous pemphigoid or Fournier\u2019s gangrene associated with sodium-glucose cotransporter 2 inhibitor therapy. Knowledge of the dermatological manifestations of CADRs is important in clinical practice. Recognition of a skin lesion resulting from an adverse drug reaction allows for appropriate management, which in this case is primarily related to drug discontinuation. This is particularly important in the treatment of T2DM since this disease has a high prevalence in the elderly, who are at higher risk of adverse drug reactions.<\/jats:p>","DOI":"10.3390\/ph17070847","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:42:30Z","timestamp":1719546150000},"page":"847","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Skin-Related Adverse Reactions Induced by Oral Antidiabetic Drugs\u2014A Review of Literature and Case Reports"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7696-5325","authenticated-orcid":false,"given":"Justyna","family":"Kowalska","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiello\u0144ska 4, 41-200 Sosnowiec, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6918-3330","authenticated-orcid":false,"given":"Dorota","family":"Wrze\u015bniok","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiello\u0144ska 4, 41-200 Sosnowiec, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2023). Diabetes: A Defining Disease of the 21st Century. Lancet, 401, 2087. Available online: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673623012965?via%3Dihub.","DOI":"10.1016\/S0140-6736(23)01296-5"},{"key":"ref_2","unstructured":"(2024, January 05). Global Diabetes Cases to Soar from 529 Million to 1.3 Billion by 2050. Available online: https:\/\/www.healthdata.org\/news-events\/newsroom\/news-releases\/global-diabetes-cases-soar-529-million-13-billion-2050."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5897\/JPAP2013.0001","article-title":"The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus","volume":"4","author":"Ozougwu","year":"2013","journal-title":"J. Physiol. Pathophysiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ahmad, S.I. (2013). type 2 diabetes mellitus, pandemic in 21st century. Diabetes an Old Disease, a New Insight, Landes Bioscience and Springer Science + Business Media, LLC.","DOI":"10.1007\/978-1-4614-5441-0"},{"key":"ref_5","unstructured":"Goyal, R., Singhal, M., and Jialal, I. (2024, January 05). Type 2 diabetes, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513253\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 diabetes mellitus: A review of current trends","volume":"27","author":"Olokoba","year":"2012","journal-title":"Oman Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5603\/DK.2017.0006","article-title":"Pros and cons of polypharmacy in elderly patients with diabetes","volume":"6","author":"Wojtczak","year":"2017","journal-title":"Clin. Diabetol."},{"key":"ref_8","unstructured":"Feingold, K.R. (2024, January 15). Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes, Endotext [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279141\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cohen Sabban, E.N., Puchulu, F.M., and Cusi, K. (2018). Dermatology and Diabetes, Springer.","DOI":"10.1007\/978-3-319-72475-1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","article-title":"Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems","volume":"27","author":"Raschi","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis. NMCD"},{"key":"ref_12","first-page":"83","article-title":"Dermatological syndromes in diabetes mellitus\u2014Practicalaspects of diagnostics, prophylactics and therapy indiabetological care","volume":"18","year":"2014","journal-title":"Med. Metab."},{"key":"ref_13","first-page":"287","article-title":"Diabetic Skin complications: A need for reorganizing the categories of diabetes-associated complications","volume":"6","author":"Wertheimer","year":"2004","journal-title":"Isr. Med. Assoc. J. IMAJ"},{"key":"ref_14","first-page":"108","article-title":"Skin dysfunction in diabetes. Part 1\u2014Function of skin cells","volume":"3","author":"Araszkiewicz","year":"2014","journal-title":"Viamedica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2337\/diabetes.50.7.1627","article-title":"Glucose effects on skin keratinocytes: Implications for diabetes skin complications","volume":"50","author":"Spravchikov","year":"2001","journal-title":"Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/diab.26.4.284","article-title":"Abnormalities in proliferation and protein synthesis in skin fibroblast cultures from patients with diabetes mellitus","volume":"26","author":"Rowe","year":"1977","journal-title":"Diabetes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3949\/ccjm.75.11.772","article-title":"Skin manifestations of diabetes","volume":"75","author":"Bootsma","year":"2008","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_18","unstructured":"Go\u017adzialska, A., and Ja\u015bkiewicz, J. (2013). Dermatozy Sk\u00f3rne\u2014Aktualne Problemy Cukrzycy. Wsp\u00f3\u0142czesne Kierunki w Medycynie Prewencyjnej, Oficyna Wydawnicza AFM."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The antihyperglycaemic effect of metformin: Therapeutic and cellular mechanisms","volume":"58","author":"Wiernsperger","year":"1999","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Herman, R., Kravos, N.A., Jensterle, M., Jane\u017e, A., and Dol\u017ean, V. (2022). Metformin and insulin resistance: A review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031264"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/cd21-0043","article-title":"Recommendations for practical use of metformin, a central pharmacological therapy in type 2 diabetes","volume":"40","author":"Vieira","year":"2022","journal-title":"Clin. Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2023). Standards of Care in Diabetes\u20142023 abridged for primary care providers. Clin. Diabetes, 41, 4\u201331.","DOI":"10.2337\/cd23-as01"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pantea Stoian, A.M., and Rizzo, M. (2020). Metformin indications, dosage, adverse reactions, and contraindications. Metformin, IntechOpen.","DOI":"10.5772\/intechopen.77824"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/diabetology3010008","article-title":"Cutaneous reactions to antidiabetic agents: A narrative review","volume":"3","author":"Boccardi","year":"2022","journal-title":"Diabetology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1345\/aph.1E074","article-title":"Erythema multiforme from metformin","volume":"38","author":"Burger","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000246152","article-title":"Lichen planus associated with metformin therapy","volume":"194","author":"Azzam","year":"1997","journal-title":"Dermatology"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mumoli, L., Gambardella, A., Labate, A., Succurro, E., De Sarro, G., Arturi, F., and Gallelli, L. (2014). Rosacea-like facial rash related to metformin administration in a young woman. BMC Pharmacol. Toxicol., 15.","DOI":"10.1186\/2050-6511-15-3"},{"key":"ref_28","first-page":"740","article-title":"Metformin induced bullous pemphigoid\u2014A rare case report","volume":"31","author":"Pokharel","year":"2022","journal-title":"J. Pak. Assoc. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D37CF866X9","article-title":"Psoriasiform drug eruption associated with metformin hydrochloride: A case report","volume":"9","author":"Koca","year":"2003","journal-title":"Dermatol. Online J."},{"key":"ref_30","first-page":"703","article-title":"Photosensitivity induced by metformin: A report of 3 cases","volume":"87","author":"Kastalli","year":"2009","journal-title":"Tunis. Med."},{"key":"ref_31","first-page":"1272","article-title":"Metformin-induced pseudoporphyria","volume":"11","author":"Lenfestey","year":"2012","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1970","DOI":"10.1097\/MJT.0000000000000292","article-title":"DRESS syndrome following metformin administration: A case report and review of the literature","volume":"23","author":"Voore","year":"2016","journal-title":"Am. J. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rzepka, Z., Respondek, M., Rok, J., Beberok, A., Proinsias, K.\u00d3., Gryko, D., and Wrze\u015bniok, D. (2018). Vitamin B12 deficiency induces imbalance in melanocytes homeostasis\u2014A cellular basis of hypocobalaminemia pigmentary manifestations. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092845"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/15569527.2013.861477","article-title":"Dermatological findings of vitamin b12 deficiency and resolving time of these symptoms","volume":"33","author":"Demir","year":"2014","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/bmj.293.6545.483","article-title":"Leucocytoclastic vasculitis and pneumonitis induced by metformin","volume":"293","author":"Klapholz","year":"1986","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1345\/aph.1H155","article-title":"Rare case of metformin-induced leukocytoclastic vasculitis","volume":"40","author":"Salem","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4103\/0253-7613.77379","article-title":"Metformin allergy","volume":"43","author":"Wiwanitkit","year":"2011","journal-title":"Indian J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/11593230-000000000-00000","article-title":"Metformin-induced leukocytoclastic vasculitis: A case report","volume":"13","author":"Czarnowicki","year":"2012","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_39","unstructured":"Sheh, T., and Tsai, I. (2023, November 10). Metformin Vasculitis: A Rare Reaction to a Common Medication. Available online: https:\/\/www.proceedings.med.ucla.edu\/wp-content\/uploads\/2016\/08\/A160602TS-WH-edited.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.18203\/2319-2003.ijbcp20195293","article-title":"Hypersensitivity reaction with metformin: A case report","volume":"8","author":"Vashisht","year":"2019","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"ref_41","first-page":"14","article-title":"What are these lesions that spread from the lips?","volume":"23","author":"Monroe","year":"2010","journal-title":"J. Am. Acad. Physician Assist."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.12659\/AJCR.896424","article-title":"Metformin-induced fixed-drug eruption confirmed by multiple exposures","volume":"17","author":"Steber","year":"2016","journal-title":"Am. J. Case Rep."},{"key":"ref_43","first-page":"555632","article-title":"Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a metformin plus simvastatin in a tertiary care teaching hospital in Punjab","volume":"4","author":"Amit","year":"2017","journal-title":"Curr. Res. Diabetes Obes. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/DAD.0000000000000800","article-title":"Metformin-induced generalized fixed drug eruption with cutaneous hemophagocytosis","volume":"39","author":"Lopez","year":"2017","journal-title":"Am. J. Dermatopathol."},{"key":"ref_45","first-page":"763","article-title":"A Case of fixed drug eruption induced by inactive ingredients of metformin","volume":"62","author":"Togawa","year":"2019","journal-title":"Diabetes"},{"key":"ref_46","first-page":"e18599","article-title":"Fixed drug eruption secondary to four anti-diabetic medications: An unusual case of polysensitivity","volume":"13","author":"Fleifel","year":"2021","journal-title":"Cureus"},{"key":"ref_47","first-page":"6353919","article-title":"Metformin-induced generalized bullous fixed-drug eruption with a positive dechallenge-rechallenge test: A case report and literature review","volume":"2023","author":"Momen","year":"2023","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_48","unstructured":"(2024, May 07). FDA Adverse Events Reporting System (FAERS) Public Dashboard, Available online: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis."},{"key":"ref_49","unstructured":"(2024, May 07). EudraVigilance\u2014European Database of Suspected Adverse Drug Reaction Reports. Available online: https:\/\/www.adrreports.eu\/en\/search.html."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"State of the art paper sulfonylureas and their use in clinical practice","volume":"4","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"117955142210746","DOI":"10.1177\/11795514221074663","article-title":"Position of sulfonylureas in the current era: Review of national and international guidelines","volume":"15","author":"Mohan","year":"2022","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s13410-023-01192-6","article-title":"Time to reposition sulfonylureas in type 2 diabetes management in indian context: A pragmatic practical approach","volume":"43","author":"Das","year":"2023","journal-title":"Int. J. Diabetes Dev. Ctries."},{"key":"ref_53","unstructured":"Costello, R., Nicolas, S., and Shivkumar, A. (2023, December 06). Sulfonylureas, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513225\/."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2165\/00003495-200464120-00006","article-title":"The role of sulphonylureas in the management of type 2 diabetes mellitus","volume":"64","author":"Rendell","year":"2004","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1503\/cmaj.1031414","article-title":"Oral antihyperglycemic therapy for type 2 diabetes mellitus","volume":"172","author":"Cheng","year":"2005","journal-title":"Can. Med. Assoc. J."},{"key":"ref_56","first-page":"103","article-title":"Oral administration of Orinase (tolbutamide); clinical observations of effect on nondiabetic and diabetic humans","volume":"88","author":"Lambert","year":"1958","journal-title":"Calif. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00613824","article-title":"Plasma chlorpropamide: A critical factor in chlorpropamide-alcohol flush","volume":"24","author":"Jerntorp","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2337\/diab.30.9.788","article-title":"Increase of plasma acetaldehyde: An objective indicator of the chlorpropamide alcohol flush","volume":"30","author":"Jerntorp","year":"1981","journal-title":"Diabetes"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2125.2007.02863.x","article-title":"Glimepiride-induced vasculitis: A case report","volume":"64","author":"Hmouda","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_60","first-page":"e45965","article-title":"Acute exfoliative dermatitis\/erythroderma secondary to gliclazide","volume":"15","author":"Ahmed","year":"2023","journal-title":"Cureus"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/15569527.2013.870188","article-title":"Erythroderma secondary to gliclazide: A case report","volume":"33","author":"Ozuguz","year":"2014","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_62","first-page":"103","article-title":"Phototoxicity to sulphonamide derived oral antidiabetics and diuretics. Comparative in vitro and in vivo investigations","volume":"11","author":"Selvaag","year":"1997","journal-title":"In Vivo"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0781.1997.tb00100.x","article-title":"Phototoxicity to sulphonamide-derived oral antidiabetics and diuretics: Investigations in hairless mice","volume":"13","author":"Selvaag","year":"1997","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11882-002-0033-y","article-title":"Allergic adverse reactions to sulfonamides","volume":"2","author":"Vial","year":"2002","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0897190007305686","article-title":"Sulfonamide Allergy and Possible Cross-Reactivity","volume":"20","author":"Kourlas","year":"2007","journal-title":"J. Pharm. Pract."},{"key":"ref_66","first-page":"21","article-title":"Thrombocytopenia due to sulfonamide cross-sensitivity","volume":"81","author":"Bretza","year":"1982","journal-title":"Wis. Med. J."},{"key":"ref_67","first-page":"235","article-title":"Leukocytoclastic vasculitis induced by use of glyburide: A case of possible cross-reaction of a sulfonamide and a sulfonylurea","volume":"71","author":"Bukhalo","year":"2003","journal-title":"Cutis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1592\/phco.22.8.637.33200","article-title":"Celecoxib-induced erythema multiforme with glyburide cross-reactivity","volume":"22","author":"Ernst","year":"2002","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.14499","article-title":"Fatal toxic epidermal necrolysis probably related to glimepiride in a patient with a medical history of hypersensitivity to sulfamethoxazole\u2013trimethoprim","volume":"87","author":"Ouni","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0190-9622(99)70335-X","article-title":"Glipizide-induced pigmented purpuric dermatosis","volume":"41","author":"Adams","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1440-0960.2004.00023.x","article-title":"Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride","volume":"44","author":"Noakes","year":"2003","journal-title":"Australas. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/pdi.644","article-title":"Stevens\u2013Johnson syndrome with visceral arteritis due to sulphonylurea therapy","volume":"21","author":"Duncan","year":"2004","journal-title":"Pract. Diabetes Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/j.1365-4632.2012.05521.x","article-title":"Acute generalized exanthematous pustulosis induced by gliclazide: A case report","volume":"52","author":"Mota","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"19619","DOI":"10.5070\/D3199019619","article-title":"A case of glyburide-induced leukocytoclastic vasculitis","volume":"19","author":"Henley","year":"2013","journal-title":"Dermatol. Online J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.therap.2018.01.008","article-title":"Glibenclamide-induced photodistributed lichenoid eruption: An unusual association","volume":"73","author":"Chadli","year":"2018","journal-title":"Therapies"},{"key":"ref_76","first-page":"155","article-title":"A rare case of drug reaction with eosinophilia and systemic symptoms (DRESS): Glimepiride, the unlikely culprit","volume":"13","author":"Dev","year":"2018","journal-title":"Maedica"},{"key":"ref_77","first-page":"e31094","article-title":"a generalized form of lichen planus pemphigoid induced by an oral antidiabetic","volume":"14","author":"Ajaaouani","year":"2022","journal-title":"Cureus"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Jabbour, S.A., Ibrahim, N.E., and Argyropoulos, C.P. (2022). Physicians\u2019 considerations and practice recommendations regarding the use of sodium-glucose cotransporter-2 inhibitors. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206051"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"E1128","DOI":"10.1503\/cmaj.190047","article-title":"Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering","volume":"191","author":"Neuen","year":"2019","journal-title":"CMAJ Can. Med. Assoc. J. J. Assoc. Medicale Can."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","article-title":"SGLT2 inhibitors: Are they safe?","volume":"130","author":"Filippatos","year":"2018","journal-title":"Postgrad. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","article-title":"Short-Term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: Considerations for their appropriate use to avoid serious adverse events","volume":"14","author":"Yabe","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_82","first-page":"59","article-title":"A case of bullous pemphigoid associated with the administration of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor","volume":"61","author":"Ikehara","year":"2018","journal-title":"J. Jpn. Diabetes Soc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1574886311666160405110515","article-title":"Generalized intense pruritus during canagliflozin treatment: Is it an adverse drug reaction?","volume":"13","author":"Vasapollo","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.25179\/tjem.2018-63449","article-title":"Case report: Fixed drug eruption caused by dapagliflozin","volume":"23","author":"KeskiN","year":"2019","journal-title":"Turk. J. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"937","DOI":"10.7150\/ijms.22224","article-title":"Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors","volume":"15","author":"Sakaeda","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/14656566.2016.1219341","article-title":"Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Final results of a post-marketing surveillance study","volume":"17","author":"Yokote","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14656566.2018.1434145","article-title":"safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: A subgroup analysis of the STELLA-LONG TERM study","volume":"19","author":"Maegawa","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/ced.15385","article-title":"Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus: A nationwide population-based cohort study","volume":"47","author":"Ma","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2337\/dbi18-0006","article-title":"Sodium-glucose cotransporter 2 inhibitors: A case study in translational research","volume":"68","author":"Beitelshees","year":"2019","journal-title":"Diabetes"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dme.13508","article-title":"Fournier\u2019s gangrene in a man on empagliflozin for treatment of type 2 diabetes","volume":"34","author":"Kumar","year":"2017","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40800-019-0105-8","article-title":"Fournier\u2019s gangrene in a patient with type 2 diabetes mellitus treated with empagliflozin: A case report","volume":"6","author":"Nagano","year":"2019","journal-title":"Drug Saf.-Case Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2337\/cd21-0015","article-title":"Sodium-glucose cotransporter 2 inhibitor use associated with Fournier\u2019s gangrene: A review of case reports and spontaneous post-marketing cases","volume":"40","author":"Tran","year":"2022","journal-title":"Clin. Diabetes Publ. Am. Diabetes Assoc."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13611","article-title":"A safety update on sodium glucose co-transporter 2 inhibitors","volume":"21","author":"Fitchett","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_94","unstructured":"Chi, W., and Lim-Tio, S. (2016, January 25). Fournier\u2019s syndrome: A life threatening complication of SGLT2 Inhibition in poorly controlled diabetes mellitus. Proceedings of the 2016 Joint Annual Scientific Meeting of the Australian Diabetes Educators Association (ADEA) and the Australian Diabetes Society (ADS), Gold Coast, Australia."},{"key":"ref_95","first-page":"97","article-title":"SLGT-2 inhibitor dapagliflozin and Fournier\u2019s gangrene: A life-threatening severe adverse effect","volume":"35","author":"Omer","year":"2018","journal-title":"Diabet. Med."},{"key":"ref_96","first-page":"e5173","article-title":"Early presentation of a rare complication of sodium-glucose cotransporter-2 inhibitors 10 days after initiation: Case report and literature review","volume":"11","author":"Elshimy","year":"2019","journal-title":"Cureus"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/1753-0407.12896","article-title":"Fournier\u2019s gangrene in a patient on dapagliflozin treatment for type 2 diabetes","volume":"11","author":"Onder","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_98","first-page":"e5778","article-title":"Fournier\u2019s gangrene under sodium-glucose cotransporter 2 inhibitor therapy as a life-threatening adverse event: A case report and review of the literature","volume":"11","author":"Rodler","year":"2019","journal-title":"Cureus"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e237784","DOI":"10.1136\/bcr-2020-237784","article-title":"Fournier\u2019s gangrene with dapagliflozin in a rural hospital: A case report","volume":"14","author":"Elbeddini","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijscr.2020.11.100","article-title":"Fournier\u2019s gangrene under sglt-2 inhibitor therapy: A literature review and case report","volume":"77","author":"Prytz","year":"2020","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.endinu.2019.12.007","article-title":"Fournier\u2019s gangrene and SGLT2 inhibitors: A case study","volume":"67","year":"2020","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e921536","DOI":"10.12659\/AJCR.921536","article-title":"Fournier\u2019s gangrene and diabetic ketoacidosis associated with sodium glucose co-transporter 2 (SGLT2) inhibitors: Life-threatening complications","volume":"21","author":"Kasbawala","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.3393\/ac.2020.06.22","article-title":"Fournier gangrene in a patient with type 2 diabetes mellitus treated with dapagliflozin: A case report","volume":"37","author":"Moon","year":"2021","journal-title":"Ann. Coloproctology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/17425255.2014.907274","article-title":"The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]","volume":"10","author":"Filippatos","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e01029","DOI":"10.1002\/prp2.1029","article-title":"Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?","volume":"10","author":"Jones","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_106","unstructured":"(2023, December 28). NICE Guidance\u2014Gliptin Therapy in Type 2 Diabetes. Available online: https:\/\/gpnotebook.com\/pages\/diabetes-and-endocrinology\/nice-guidance-gliptin-therapy-in-type-2-diabetes."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5308582","DOI":"10.1155\/2018\/5308582","article-title":"DPP-4 inhibitors as treatments for type 1 diabetes mellitus: A systematic review and meta-analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-015-0294-0","article-title":"Antidiabetic treatment with gliptins: Focus on cardiovascular effects and outcomes","volume":"14","author":"Fisman","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"101275","DOI":"10.1016\/j.diabet.2021.101275","article-title":"Efficacy\/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes","volume":"47","author":"Scheen","year":"2021","journal-title":"Diabetes Metab."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Huang, J., Jia, Y., Sun, S., and Meng, L. (2020). Adverse event profiles of dipeptidyl peptidase-4 inhibitors: Data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00447-w"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dmrr.2502","article-title":"Safety of saxagliptin: Events of special interest in 9156 patients with type 2 diabetes mellitus","volume":"30","author":"Hirshberg","year":"2014","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"bcr2017219998","DOI":"10.1136\/bcr-2017-219998","article-title":"Linagliptin-associated blistering and ulceration","volume":"2017","author":"Psomadakis","year":"2017","journal-title":"BMJ Case Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/ced.15144","article-title":"Dipeptidyl peptidase-4 inhibitor-associated cutaneous eruptions: A retrospective observational study","volume":"47","author":"Duraisamy","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2332\/allergolint.13-LE-0669","article-title":"Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: A case report and mini-review of the published work","volume":"63","author":"Nakai","year":"2014","journal-title":"Allergol. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D30D70K7B2","article-title":"Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia\u00ae)","volume":"18","author":"Stricklin","year":"2012","journal-title":"Dermatol. Online J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/1346-8138.14076","article-title":"Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor: A case report","volume":"45","author":"Okauchi","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/14740338.2015.977863","article-title":"DPP-4 inhibitors: Focus on safety","volume":"14","author":"Tella","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1440-0960.2011.00783.x","article-title":"Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor","volume":"53","year":"2012","journal-title":"Australas. J. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Tasanen, K., Varpuluoma, O., and Nishie, W. (2019). Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01238"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","article-title":"Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study","volume":"87","author":"Salemme","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: Estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish nationwide registry study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3325\/cmj.2020.61.93","article-title":"The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: A retrospective study","volume":"61","year":"2020","journal-title":"Croat. Med. J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"107515","DOI":"10.1016\/j.jdiacomp.2019.107515","article-title":"The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study","volume":"34","author":"Guo","year":"2020","journal-title":"J. Diabetes Complicat."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12967-021-03192-8","article-title":"Bullous pemphigoid in diabetic patients treated by gliptins: The other side of the coin","volume":"19","author":"Chouchane","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/bjd.16479","article-title":"Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"178","author":"Horikawa","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1346-8138.14245","article-title":"Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid","volume":"45","author":"Chijiwa","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1684\/ejd.2018.3371","article-title":"Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: Does this differ from common bullous pemphigoid?","volume":"28","author":"Patsatsi","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2340\/00015555-3166","article-title":"Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4\/CD26 in bullous pemphigoid","volume":"99","author":"Lindgren","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Deacon, C.F. (2019). Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00080"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/25785826.2019.1619233","article-title":"Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: A recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics","volume":"42","author":"Nishie","year":"2019","journal-title":"Immunol. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: Report of two cases","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. a case report and review of literature","volume":"8","author":"Attaway","year":"2014","journal-title":"J. Dermatol. Case Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/fcp.12083","article-title":"Bullous pemphigoid induced by vildagliptin: A report of three cases","volume":"29","author":"Jacobsoone","year":"2015","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Aranburu","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous pemphigoid associated with linagliptin treatment","volume":"152","author":"Haber","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/15569527.2016.1211670","article-title":"A case of bullous pemphigoid induced by vildagliptin","volume":"36","author":"Keseroglu","year":"2017","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000443330","article-title":"Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors\u2014One due to linagliptin","volume":"232","year":"2016","journal-title":"Dermatology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/ijd.13705","article-title":"Linagliptin-induced bullous pemphigoid","volume":"56","author":"Esposito","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2169\/internalmedicine.8703-16","article-title":"Bullous pemphigoid associated with the dipeptidyl peptidase-4 inhibitor sitagliptin in a patient with liver cirrhosis complicated with rapidly progressive hepatocellular carcinoma","volume":"56","author":"Harada","year":"2017","journal-title":"Intern. Med. Tokyo Jpn."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1111\/1346-8138.13941","article-title":"Bullous pemphigoid following the replacement of vildagliptin with anagliptin","volume":"44","author":"Oya","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjd.15111","article-title":"Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP 180","volume":"176","author":"Sakai","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Mai, Y., Nishie, W., Sato, K., Hotta, M., Izumi, K., Ito, K., Hosokawa, K., and Shimizu, H. (2018). Bullous pemphigoid triggered by thermal burn under medication with a dipeptidyl peptidase-IV inhibitor: A case report and review of the literature. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00542"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/1346-8138.14254","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis","volume":"45","author":"Maki","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/jdi.12695","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases","volume":"9","author":"Yoshiji","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/jpgm.JPGM_120_19","article-title":"Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor\u2014A case report","volume":"65","author":"Karthik","year":"2019","journal-title":"J. Postgrad. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13730-020-00452-2","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01","volume":"9","author":"Hibi","year":"2020","journal-title":"CEN Case Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.dsx.2020.03.001","article-title":"Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases","volume":"14","author":"Jha","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e932356","DOI":"10.12659\/AJCR.932356","article-title":"Atypical bullous pemphigoid after linagliptin intake","volume":"22","author":"Dbouk","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2021.08.004","article-title":"Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes","volume":"103","author":"Kitao","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000525520","article-title":"DPP4 inhibitor-induced bullous pemphigoid in patients with diabetes and chronic kidney disease: Clinical case series","volume":"147","author":"Charitaki","year":"2023","journal-title":"Nephron"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000480498","article-title":"Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid","volume":"233","author":"Schaffer","year":"2017","journal-title":"Dermatology"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Lambadiari, V., Kountouri, A., Kousathana, F., Korakas, E., Kokkalis, G., Theotokoglou, S., Palaiodimou, L., Katsimbri, P., Ikonomidis, I., and Theodoropoulos, K. (2021). The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: A ten-year prospective observational study. BMC Endocr. Disord., 21.","DOI":"10.1186\/s12902-021-00689-7"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: A case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"Moulis","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes","volume":"42","author":"Douros","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/ajd.13100","article-title":"dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis","volume":"61","author":"Phan","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e3391","DOI":"10.1002\/dmrr.3391","article-title":"Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Yang","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/ijem.ijem_522_21","article-title":"A review of oral semaglutide available evidence: A new era of management of diabetes with peptide in a pill form","volume":"26","author":"Kalra","year":"2022","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_163","unstructured":"(2024, January 15). Wegovy: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jdcr.2021.07.027","article-title":"Semaglutide-associated bullous pemphigoid","volume":"15","author":"Burruss","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.anai.2022.08.735","article-title":"The first report of angioedema and anaphylaxis with temporal association to semaglutide","volume":"129","author":"Feinstein","year":"2022","journal-title":"Ann. Allergy. Asthma Immunol."},{"key":"ref_166","unstructured":"Singh, G., Can, A., and Correa, R. (2023). Pioglitazone. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_167","unstructured":"Quintanilla Rodriguez, B., and Correa, R. (2023, December 14). Rosiglitazone, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544230\/."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.eprac.2021.04.532","article-title":"Abstract #992206: A rare of adverse reactions of pioglitazone: Hypersensitivity to the active substance lactose","volume":"27","author":"Yau","year":"2021","journal-title":"Endocr. Pract."},{"key":"ref_169","unstructured":"Wexler, P. (2024). Anti diabetic agents. Encyclopedia of Toxicology, Elsevier. [4th ed.]."},{"key":"ref_170","unstructured":"Milner, Z., and Akhondi, H. (2023, December 14). Repaglinide, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559305\/."},{"key":"ref_171","first-page":"245","article-title":"Hypersensitivity to repaglinide","volume":"21","author":"Rojas","year":"2011","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_172","unstructured":"Akmal, M., and Wadhwa, R. (2023, December 20). Alpha glucosidase inhibitors, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557848\/."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(99)02135-2","article-title":"Acarbose-induced generalised erythema multiforme","volume":"354","author":"Kono","year":"1999","journal-title":"Lancet"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e14819","DOI":"10.1111\/ijcp.14819","article-title":"Association between \u03b1-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study","volume":"75","author":"Huang","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4172\/2329-6887.1000260","article-title":"The Challenges of Adverse Drug Reaction Evaluation","volume":"6","author":"Marante","year":"2018","journal-title":"J. Pharmacovigil."},{"key":"ref_176","first-page":"e59975","article-title":"Causality, severity, preventability and predictability assessments scales for adverse drug reactions: A review","volume":"16","author":"Manjhi","year":"2024","journal-title":"Cureus"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31531\/2231-5896.1000112","article-title":"An overview of various scales used in causality assessment of adverse drug reactions","volume":"12","author":"Kumar","year":"2020","journal-title":"Int. J. Pharm. Sci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/847\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:06:40Z","timestamp":1760108800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":177,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ph17070847"],"URL":"https:\/\/doi.org\/10.3390\/ph17070847","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}